ARCTICZYMES TECHNOLOGIES ASA
Operating
Enzymes for Biomanufacturing, Research, MDx | ArcticZymes
The Enzymes Experts | Solutions for molecular research, diagnostics, and therapeutics for gene therapy, vaccine production. Inventor of salt-active nucleases for biomanufacturing
Drive forskning, utvikling, produksjon, markedsføring og salg av
preparater til medisinsk bruk, biokjemikalier for forskning og
industriell anvendelse. Selskapet skal fremme utvikling av produkter
og teknologisk viten innenfor sine virksomhetsområder og kan gjøre
investeringer i andre selskaper innenfor disse områdene.
Delta i forskning og utvikling, kommersialisering, produksjon,
markedsføring og salg av bioteknologiske produkter for medisinsk,
industriell og forskningsbaserte anvendelser. Selskapet skal fremme
produkter og teknologisk viten knyttet til ovennevnte samt enhver
aktivitet som naturlig følger av eller hører sammen med dette, og skal
herunder kunne investere i andre selskap eller i egne industri- eller
forsningsanlegg.
Keywords
productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings
Organization
- CEO
- MB
- Chairman of the board
- FM
Frank Mathias1962
- Years since formation
- 31 years
- since Mar 12, 1995
- Type
- Public limited company
- VAT registered
- Yes
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 51,071,390
- 1 share class
- Total number of shareholders
- 3021
- 161 companies, 2,860 persons
- Belongs to group of
Financials
- Total operating income 2024
- 4,738,000
- NOK
- Annual total result 2024
- 6,755,000
- NOK
- Total equity 2024
- 416,733,000
- NOK
Last update: Dec 12, 2025
Locations
- Company addressSykehusvegen 23 9019 TROMSØ, Norge
Copied! - Postal addressPostboks 6463 Stakkevollan 9294 TROMSØ, Norge
Copied!
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
MB | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
FM 1962 | Chairman | - |
SB 1967 | Board Member | - |
PD 1964 | Board Member | - |
TS 1976 | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
P PRICEWATERHOUSECOOPERS AS | Auditor | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
ST 1958 | - | 4.72 % indirectly |
JR | - | 3.45 % indirectly |
AH 1964 | - | 1.31 % directly 0.15 % indirectly 1.17 % |
FR 1966 | - | 1.1 % indirectly |
EH | - | 1.04 % directly < 0.01 % indirectly 1.03 % |
Last update: Oct 24, 2024
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| NO0010014632 | 9,988,612 | 19.56 % | |
| NO0010014632 | 3,985,070 | 7.8 % | |
| NO0010014632 | 2,740,253 | 5.37 % | |
P PRO AS | NO0010014632 | 2,411,626 | 4.72 % |
| NO0010014632 | 2,166,944 | 4.24 % | |
| NO0010014632 | 2,024,317 | 3.96 % | |
| NO0010014632 | 1,182,955 | 2.32 % | |
B BELVEDERE AS | NO0010014632 | 1,159,965 | 2.27 % |
| NO0010014632 | 1,100,000 | 2.15 % | |
| NO0010014632 | 950,024 | 1.86 % | |
V VINTERSTUA AS | NO0010014632 | 797,208 | 1.56 % |
| NO0010014632 | 743,978 | 1.46 % | |
R RIISE INVEST NORD AS | NO0010014632 | 619,000 | 1.21 % |
| NO0010014632 | 611,515 | 1.2 % | |
I ISAR AS | NO0010014632 | 601,645 | 1.18 % |
N NAUDHOLMEN AS | NO0010014632 | 595,000 | 1.17 % |
K KVANTIA AS | NO0010014632 | 554,713 | 1.09 % |
N NORDNET LIVSFORSIKRING AS | NO0010014632 | 534,888 | 1.05 % |
M MIDDELBOE AS | NO0010014632 | 527,977 | 1.03 % |
D DRAGESUND INVEST AS | NO0010014632 | 521,739 | 1.02 % |
| NO0010014632 | 500,000 | 0.98 % | |
| NO0010014632 | 414,884 | 0.81 % | |
TO 1959 | NO0010014632 | 380,492 | 0.75 % |
PO | NO0010014632 | 360,000 | 0.7 % |
SH 1989 | NO0010014632 | 357,500 | 0.7 % |
H HARTVIG WENNBERG AS | NO0010014632 | 336,013 | 0.66 % |
| NO0010014632 | 308,179 | 0.6 % | |
| NO0010014632 | 300,000 | 0.59 % | |
| NO0010014632 | 284,595 | 0.56 % | |
K KUVEN INVEST AS | NO0010014632 | 276,000 | 0.54 % |
P PROGUSAN AS | NO0010014632 | 250,000 | 0.49 % |
J JOMANI AS | NO0010014632 | 247,040 | 0.48 % |
AK | NO0010014632 | 238,000 | 0.47 % |
EE | NO0010014632 | 222,323 | 0.44 % |
| NO0010014632 | 214,063 | 0.42 % | |
GT 1965 | NO0010014632 | 210,000 | 0.41 % |
VF | NO0010014632 | 204,274 | 0.4 % |
AK | NO0010014632 | 187,809 | 0.37 % |
MM 1977 | NO0010014632 | 182,223 | 0.36 % |
ST | NO0010014632 | 180,000 | 0.35 % |
D DARK CAP AS | NO0010014632 | 173,000 | 0.34 % |
JT 1965 | NO0010014632 | 170,655 | 0.33 % |
N NJR HOLDING AS | NO0010014632 | 162,000 | 0.32 % |
HA | NO0010014632 | 162,000 | 0.32 % |
PE 1967 | NO0010014632 | 161,942 | 0.32 % |
SM 1939 | NO0010014632 | 159,066 | 0.31 % |
| NO0010014632 | 153,679 | 0.3 % | |
| NO0010014632 | 150,000 | 0.29 % | |
JR 1939 | NO0010014632 | 131,015 | 0.26 % |
AM 1948 | NO0010014632 | 130,000 | 0.25 % |
JO 1941 | NO0010014632 | 130,000 | 0.25 % |
AH 1971 | NO0010014632 | 125,837 | 0.25 % |
F FINVESTIGA AS | NO0010014632 | 119,300 | 0.23 % |
OJ 1975 | NO0010014632 | 111,530 | 0.22 % |
| NO0010014632 | 111,111 | 0.22 % | |
LJ | NO0010014632 | 110,000 | 0.22 % |
BS | NO0010014632 | 108,743 | 0.21 % |
BS 1975 | NO0010014632 | 100,428 | 0.2 % |
AW 1975 | NO0010014632 | 100,000 | 0.2 % |
AE | NO0010014632 | 100,000 | 0.2 % |
AF | NO0010014632 | 97,467 | 0.19 % |
KJ | NO0010014632 | 91,120 | 0.18 % |
MF 1989 | NO0010014632 | 87,298 | 0.17 % |
| NO0010014632 | 87,124 | 0.17 % | |
| NO0010014632 | 82,439 | 0.16 % | |
| NO0010014632 | 81,460 | 0.16 % | |
TE | NO0010014632 | 81,000 | 0.16 % |
JL | NO0010014632 | 80,564 | 0.16 % |
| NO0010014632 | 78,850 | 0.15 % | |
AH 1964 | NO0010014632 | 75,000 | 0.15 % |
PO | NO0010014632 | 75,000 | 0.15 % |
| NO0010014632 | 74,704 | 0.15 % | |
G GIG EN AS | NO0010014632 | 74,201 | 0.15 % |
KO | NO0010014632 | 74,149 | 0.15 % |
F FORENEDE FORVALTNING AS | NO0010014632 | 74,000 | 0.14 % |
| NO0010014632 | 72,143 | 0.14 % | |
ME 1961 | NO0010014632 | 70,441 | 0.14 % |
| NO0010014632 | 69,260 | 0.14 % | |
TM 1968 | NO0010014632 | 69,112 | 0.14 % |
A ASKET AS | NO0010014632 | 65,779 | 0.13 % |
R RINGNES HOLDING AS | NO0010014632 | 65,267 | 0.13 % |
OS 1944 | NO0010014632 | 65,000 | 0.13 % |
A AOS HOLDING AS | NO0010014632 | 63,000 | 0.12 % |
TE | NO0010014632 | 61,070 | 0.12 % |
| NO0010014632 | 60,038 | 0.12 % | |
S SJAP AS | NO0010014632 | 60,000 | 0.12 % |
RO | NO0010014632 | 60,000 | 0.12 % |
| NO0010014632 | 58,976 | 0.12 % | |
RE 1965 | NO0010014632 | 56,719 | 0.11 % |
J JAN FR. BJERKENES HOLDING AS | NO0010014632 | 55,000 | 0.11 % |
OA | NO0010014632 | 55,000 | 0.11 % |
AK | NO0010014632 | 53,545 | 0.1 % |
AM | NO0010014632 | 52,800 | 0.1 % |
RJ | NO0010014632 | 52,000 | 0.1 % |
J JMT HOLDING AS | NO0010014632 | 51,584 | 0.1 % |
HØ | NO0010014632 | 51,051 | 0.1 % |
DR | NO0010014632 | 51,000 | 0.1 % |
SO | NO0010014632 | 50,800 | 0.1 % |
AN | NO0010014632 | 50,020 | 0.1 % |
V VIOLINA AS | NO0010014632 | 50,003 | 0.1 % |
Shares owned by the ARCTICZYMES TECHNOLOGIES ASA
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
A ARCTICZYMES AS | Ordinary shares | 109,380 | 100 % |
Last update: Jun 2, 2025
Group structure
- Total operating income 2024: NOK 4,738,000Operating profit 2024: NOK -11,406,000Employees: 0
Financials
in NOK
Summary
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 4,738,000 | 0 | 11,440,000 | 10,275,000 |
Annual Total Result | 6,755,000 | 0 | 31,248,000 | 44,013,000 |
Total assets | 425,813,000 | 0 | 408,089,000 | 465,573,000 |
Total liabilities | 9,080,000 | 0 | 20,893,000 | 114,944,000 |
Total equity | 416,733,000 | 0 | 387,197,000 | 350,629,000 |
P&L
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total operating income | 4,738,000 | 0 | 11,440,000 | 10,275,000 |
Total operating costs | 16,144,000 | 0 | 29,254,000 | 26,024,000 |
Operating result | -11,406,000 | 0 | -17,814,000 | -15,749,000 |
Financial income/costs | 20,064,000 | 0 | 57,893,000 | 71,737,000 |
Profit before tax | 8,658,000 | 0 | 40,079,000 | 55,987,000 |
Total tax & extraordinary income/cost | 1,903,000 | 0 | 8,831,000 | 11,974,000 |
Annual Total Result | 6,755,000 | 0 | 31,248,000 | 44,013,000 |
Balance overview
| Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total fixed assets | 198,422,000 | 0 | 180,936,000 | 192,947,000 |
Total current assets | 227,391,000 | 0 | 227,153,000 | 272,626,000 |
Total assets | 425,813,000 | 0 | 408,089,000 | 465,573,000 |
Short term debt | 4,716,000 | 0 | 10,666,000 | 100,472,000 |
Long term debt | 4,364,000 | 0 | 10,227,000 | 14,472,000 |
Total liabilities | 9,080,000 | 0 | 20,893,000 | 114,944,000 |
Contributed capital | 369,451,000 | 0 | 365,094,000 | 359,775,000 |
Retained earnings | 47,283,000 | 0 | 22,102,000 | -9,145,000 |
Total equity | 416,733,000 | 0 | 387,197,000 | 350,629,000 |
Total equity and liabilities | 425,813,000 | 0 | 408,089,000 | 465,573,000 |
Classification
21st company classification
BETA
Individual SMB enterprise
Category
Type of organization
Public limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations